Welcome
Support Centre
11 February 2012 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
Botulinum toxin: an adjunct in limb reconstruction - Can it reduce pain and joint complications in the lengthening phase?
Source of recordUK Trials
ISRCTNISRCTN35609758
Date ISRCTN assigned19/02/2008
Local reference number(s)SCH-07-006; Sponsor ref: 7860
Public titleBotulinum toxin: an adjunct in limb reconstruction - Can it reduce pain and joint complications in the lengthening phase?
Scientific title
AcronymBotox
Disease/condition/study domainLimb reconstruction surgery
Study hypothesisThe surgery to correct leg and foot deformities in children is a lengthy, and sometimes, difficult procedure. Metal frames are attached to the leg and/or foot and over a period of time the frame is manipulated to obtain the corrected position. During this period the muscles and skin become very tight which causes pain and may pull the joint out of position. When this happens it is sometimes necessary to stop the treatment before the best position is obtained. This means that not only is the child left with an inadequate result but that further surgery is required in the future. If the tension could be removed whilst the treatment is underway this would reduce the pain, the possibility of joint damage and potentially allow a more satisfactory to be obtained without the need for further surgery.

Botulinum toxin or Botox®, as it is commonly called, has the potential to temporarily reduce the tension in the muscles without causing permanent damage.
Design/methodologyPatient/assessor-blinded, pilot, randomised controlled trial.
Research ethics reviewAn application has been submitted to the North Sheffield Research Ethics Office. Approval pending as of 18/02/2008.
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Any child having reconstruction surgery which involves the distraction of bone and or soft tissue for femoral or tibial deformity and congenital talipes equinovarus.
2. Children between the ages of 6 and 18 years attending the Sheffield Children's NHS Trust
Participants - exclusion criteriaChildren with neurological aetiology
Patient information materialNot available in web format, please use the contact details below to request a patient information sheet
Anticipated start date01/04/2008
Anticipated end date01/04/2010
Status of trialOngoing
Target number of participants36
InterventionsPatients and the researcher collecting data will be blinded to the allocation of treatment.

Intervention group: Botulinum toxin intramuscular injections, 4 units per kg body weight
Control group: Saline injections
Primary outcome measure(s)Pain levels using a visual analogue scale validated at the Sheffield Children's Hospital. Following discharge from hospital, patients will be asked to continue recording pain level three times a day for 18 month or until discharged i.e. end of episode, which ever is first.
Secondary outcome measure(s)1. Range of movement in affected joints measured by a goniometre, recorded at each clinic visit until one month from the end of lengthening
2. Walking measured using a pedometer, recorded at each clinic visit until one month from the end of lengthening
3. Scores of the Child Health Questionnaire and the Pediatric Outcome Data Collection Instrument, administered pre-operatively, one month post-lengthening completion and one year from surgery
Sources of fundingSheffield Hospitals NHS Charitable Trust (UK)
Sponsor nameSheffield Children's NHS Foundation Trust (UK)
Sponsor detailsc/o Mrs Vee Mapunde
Clinical Research Facility
D Floor Stephenson Wing
Western Bank
Sheffield
United Kingdom
S10 2TH
Sponsor telephone+44 (0)114 2267846
Sponsor fax+44 (0)114 2267844
Sponsor emailvee.mapunde@sch.nhs.uk
Sponsor websitehttp://www.sheffieldchildrenscrf.nhs.uk
Contact nameMr James A Fernandes
Contact detailsSheffield Children's Hospital
Western Bank
Sheffield
United Kingdom
S10 2TH
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN35609758
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central